Jonathan Briggs serves as Vice President of Quality Assurance at AVEO Oncology, an LG Chem company, bringing over 35 years of industry experience, including 26 years in quality management.

Mr. Briggs most recently served as Vice President of Quality Assurance at Genocea Biosciences, Inc. (Genocea), a biopharmaceutical company developing T-cell immunotherapies targeting solid tumors. Prior to his tenure at Genocea, Mr. Briggs held the position of Vice President of Quality at Karyopharm Therapeutics and Genmab, Inc., where he oversaw the successful launch of new commercial oncology products.

Earlier in his career, Mr. Briggs served as Site Head of Quality at several commercial biopharmaceutical manufacturing facilities, including Alexion Pharmaceuticals, a subsidiary of AstraZeneca, and Lonza Biologics, Inc., where he was responsible for quality oversight of several commercial products and hosting regulatory inspections. Mr. Briggs began his career at Genentech, Inc. as a formulation scientist developing clinical drug product formulations for recombinant proteins.

Mr. Briggs received his Bachelor of Arts in Chemistry and Biology from the University of California-Santa Cruz.